Together for others

About the Report

BioPharmaChem Ireland is delighted to bring our homegrown ecosystem into full view through the publication of our Indigenous BioPharmaChem Strategy. While Ireland is globally recognised as a manufacturing powerhouse for the world’s leading firms, this report marks a significant milestone in identifying and supporting our entrepreneurs.

This strategy is built on the principle of symbiosis. It illustrates how a thriving indigenous sector—comprising over 130 mapped companies—works in tandem with global partners to create a more resilient and agile hub. These companies compete globally across the entire value chain, from early-stage drug discovery and clinical development through to commercialisation, and the crucial supports the sector relies on in between. This strategy is built around four strategic pillars: Funding, Infrastructure, Ecosystem Collaboration, and Talent.

What the Report Covers:

The Innovation Lifecycle: A close look into the bench to bedside journey, explaining the 10–15-year process of drug development which costs on average €2.6bn, and the critical "Valley of Death" where early-stage science requires the most support to reach human proof-of-concept.
The Elan Legacy: An analysis of how the transformation of Elan in the early 2000s (Ireland's first biopharma company of world scale) released the talent, capital, and "big swing" ambition that still fuels today's ecosystem.
The Current Landscape: A detailed mapping of 130+ indigenous companies categorised across nine distinct lifecycle stages. This report showcases nine case studies which examine representative companies across each category in detail.
The Wider Ecosystem: A spotlight on some of the essential network of state agencies, research and training centres, infrastructure partners, funding bodies, and regulators that provides the connective tissue for indigenous growth.
The Funding Gap: Identification of the €1.1 billion equity financing gap facing Irish companies and the urgent need for domestic capital to ensure Irish-owned IP and innovation stays rooted in Ireland.
International Benchmarking: Comparative data against leading biotech ecosystem hubs like Denmark and Flanders to identify where Ireland can take inspiration from to close structural gaps. The Roadmap for Action: A strategic call for the Government to name the indigenous biopharmachem sector as a distinct priority within the National Life Sciences Strategy. This strategy is a call to action for policymakers, funders, and industry leaders to recognise the sector’s value and commit to a future where Ireland supports its current homegrown companies to scale, while fostering the next generation of Irish-founded biopharmachem companies from the very start.
The Roadmap for Action: A strategic call for the Government to name the indigenous biopharmachem sector as a distinct priority within the National Life Sciences Strategy. This strategy is a call to action for policymakers, funders, and industry leaders to recognise the sector’s value and commit to a future where Ireland supports its current homegrown companies to scale, while fostering the next generation of Irish-founded biopharmachem companies from the very start.